clinical trial
Document de presse
2021.05.12
Inserm teams led by Laurent Reber (Infinity, Toulouse) and Pierre Bruhns (Humoral Immunity, Institut Pasteur, Paris) and French company NEOVACS have developed...
News
2020.08.04
Resistance to artemisinin, the main component of current antimalarial treatments recommended by WHO, is widespread in South-East Asia, but has not been...
News
2020.07.22
Aptamers can be thought of as analogs of antibodies entirely composed of nucleic acids (DNA or RNA). They can be used in a wide range of applications but they...
News
2021.05.05
Malaria remains a major public health burden in some world regions. In 2018, 237,000 cases were reported in Brazil, 91.5% of them caused by the parasite...
News
2021.03.30
Since the beginning of the COVID-19 pandemic, and increasingly rapidly thereafter, the Institut Pasteur International Network has drawn heavily on all its...
News
2021.03.24
ERA4TB (the European Regimen Accelerator for Tuberculosis) is a 6-year public-private partnership with a total budget of over €200M that began in 2020 with the...
News
2021.03.11
Two projects have been accepted into the Institut Pasteur Innovation Accelerator, an initiative to improve the development potential of the Institut Pasteur's...
Document de presse
2021.01.25
Since early 2020, the Institut Pasteur has been engaged in research in several of its areas of scientific expertise, including virology, diagnostics,...
News
2021.01.20
Diarrheal diseases are the world's second leading cause of death in children aged under 5 years, and of these, bacillary dysentery or shigellosis remains a...
Document de presse
2020.12.28
Throughout the world, long-term care facilities have been high-risk sites for virus spread since the emergence of the COVID-19 epidemic. In this context, the...